The publisher explores UCB’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (27 July 2020)
Model updates (20 May 2020)
Model updates (20 February 2020)
Model updates (25 July 2019)
Snapshot
- Overview - UCB will experience impressive growth of its core portfolio of CNS and I&I products through 2021, but patent expiries will cause growth to slow over the long term.
- Key themes - [1] UCB will see solid near-term revenue growth due to its strong immunology and neurology assets [2] UCB saw several positive readouts from the Phase III program for bimekizumab in late 2019 that bode well for future uptake of the product [3] Growth from pipeline products - bimekizumab, zilucoplan, and rozanolixizumab - and recently launched Nayzilam and Evenity will see UCB increase revenues over the forecast period [4] UCB has several sizable brands with upcoming loss of exclusivity: Vimpat in 2022, Cimzia in 2024, and Briviact in 2026.
Model updates (27 July 2020)
- Bimekizumab forecast adjusted higher due to recent clinical trial results showing superiority to current standard-of-care
- Zilucoplan forecast added after closing of Ra Pharma acquisition
- Padsevonil forecast removed after UCB formally suspends program.
Model updates (20 May 2020)
- Padsevonil forecast lowered due to disappointing results from the Phase IIb ARISE trial.
Model updates (20 February 2020)
- Cimzia forecast adjusted higher
- Evenity forecast adjusted in 5EU and RoW to reflect approval and launch in first half of 2020
- Bimekizumab forecast adjusted higher due to strong results from three Phase III trials - BE VIVID, BE READY, and BE SURE.
Model updates (25 July 2019)
- Cimzia forecast adjusted higher due to growth in new patient populations, such as women of childbearing age and people living with psoriasis
- Vimpat forecast adjusted higher due to market share gains in all regions
- Briviact forecast adjusted higher due to continued growth in all regions
- Evenity launch in Europe delayed due to negative CHMP opinion and UCB appeal
- Nayzilam forecast added
- Padsevonil forecast added
- Rozanolixizumab forecast added.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview